

NAME: Jenny L. Wilkerson

PRESENT TITLE: Assistant Professor

OFFICE ADDRESS: 185 South Orange Avenue, MSB F-543 Newark, NJ 07103

E-MAIL ADDRESS: jlw427@njms.rutgers.edu

CITIZENSHIP: United States of America

EDUCATION:

- A. Undergraduate Graduate and Professional
Northwest Missouri State University
Maryville, MO
Bachelor of Science (Cellular/Molecular Biology) 12/17/2004
- B. Graduate and Professional
University of New Mexico
Albuquerque, NM
Doctor of Philosophy (Biomedical Sciences) 12/15/2012

POSTGRADUATE TRAINING:

Postdoctoral Appointments
Virginia Commonwealth University, Richmond, VA
Pharmacology and Toxicology
04/2013-10/2017

ACADEMIC APPOINTMENTS:

Anesthesiology
Rutgers University (New Jersey Medical School)
Assistant Professor
01/01/2026-Current

Pharmaceutical Sciences
Texas Tech University Health Sciences Center (School of Pharmacy)
Assistant Professor
01/01/2023-12/31/2026

Pharmaceutical Sciences
Texas Tech University Health Sciences Center (School of Pharmacy)
Research Assistant Professor
12/01/2021-12/31/2022

Pharmacodynamics
University of Florida (College of Pharmacy)
Research Assistant Professor
11/15/2017-11/30/2021

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Society for Neuroscience
Member
2009 – Current

International Cannabinoid Research Society
Member
2011 – Current

Annual Meeting Organizing Committee
2017

Society for the Advancement of Native Americans and Chicanos in Science
Member
2007 – Current

American Society for Pharmacology & Experimental Therapeutics
Member
2015 – Current
Elected Councilor, Behavioral Pharmacology Executive Committee
2023-2026

College on the Problems of Drug Dependence
Elected Member
2019 – Current

Society for Nicotine and Tobacco Research
Member
2023 – Current
Trainee Advisory Committee
2023-2024

US Association for the Study of Pain
Member
2023 – Current
Annual Meeting Organizing Committee
2024-2026

International Association for the Study of Pain
Member
2024 – Current

HONORS AND AWARDS:

Mary Abood Women in Cannabinoid Research Award
International Cannabinoid Research Society
June 2026

P3 Teaching Team of the Year Award – Integrated Therapy and Practice V:
Neurosensory/Psychiatry
Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center
May 2025, May 2024

Graduate Mentor of the Year Award
Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center
May 2024

President's Award – Early Career Investigator
Texas Tech University Health Sciences Center
Nov. 2023

Faculty Media Excellence Award
University of Florida College of Pharmacy
June 2019

Linton Poodry Advanced Leadership Institute
SACNAS/ AAAS
July 2018

*Postdoctoral Scholar Award
Pharmacology and Toxicology Department, Virginia Commonwealth University
June 2017*

*Mitchell Max early investigator award finalist
11th annual NIH pain consortium symposium
May 2016*

*Monique and George Braude Travel Award
International Cannabinoid Research Society
2016, 2015, 2014*

*Society for Neuroscience Travel Award
Virginia Society for Neuroscience
Nov. 2015*

*Society for Neuroscience Diversity Travel Award
National Institutes on Drug Addiction
Nov. 2015*

*Outstanding Postdoctoral Fellow Presentation Award
International Cannabinoid Research Society
July 2015*

*Training in Neurotherapeutics and Discovery Development Short Course
University of California, Davis/ National Institute on Neurological Diseases and Stroke
May 2015*

*Ruth L. Kirschstein F32 Individual National Research Service Award, (F32DA038493)
National Institute on Drug Abuse
2015-2017*

*Young Investigator's Travel Award
American Pain Society
May 2012*

*Cover Image of Journal
PAIN
May 2012*

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

*Standing Study Section Member: Drug Discovery and Molecular Pharmacology B – (DMPB)
National Institutes of Health
2024-2028*

*Ad Hoc/Temporary Study Section Reviewer - NINDS ZNS1 SRB V(03) Special Emphasis Panel,
Molecular and Cellular Neuropharmacology (MCNP), Neurobiology of Pain and Itch (NPI), Drug
Discovery and Molecular Pharmacology B – (DMPB)
National Institutes of Health
2023-2024*

SERVICE ON MAJOR COMMITTEES:

*Medical School/University (Name, Inclusive Dates)
Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy
(Continuing Education Committee, 2024-2026)*

*Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy
(Professionalism Committee, 2023-2024)*

University of Florida, College of Pharmacy (*Task Force to Improve PharmD Education on the Black/ Person of Color Experience and Health Inequities, 2020-2021*)
University of Florida, College of Pharmacy (*ACPE Self-Assessment Committee, 2019-2020*)

Editorial Boards (*Journal Name, Inclusive Dates*)

Editor (*Scientific Reports, 2026-Current*)
Associate Editor (*Frontiers Pain Research, 2023-Current*)
Guest Co-editor (*Special interest edition of Pharmacology, Biochemistry & Behavior: Synthetic Cannabinoids, 2019-2020*)

AdHoc Reviewer (*Journal Name, Inclusive Dates*)

(*Physiology and Behavior, 2025*)
(*European Journal of Pain, 2025*)
(*Pharmacology, Biochemistry and Behavior, 2025, 2020, 2019*)
(*Neuroscience Letters, 2025, 2023*)
(*Neuropharmacology, 2025, 2024, 2023, 2022, 2020*)
(*Frontiers in Neurology, 2025*)
(*Pharmacological Reports, 2024, 2023, 2019*)
(*Behavioral Pharmacology, 2024, 2021, 2020*)
(*International Journal of Neuropsychopharmacology, 2024*)
(*Sapenza University Research Committee (Rome) Grant Review, 2024*)
(*State of California Center for Medicinal Cannabis Research (CMCR) Grant Review, 2024*)
(*Journal of Neuroinflammation, 2024*)
(*Journal of Pharmacology and Experimental Therapeutics, 2026, 2024, 2020*)
(*Cannabis and Cannabinoid Research, 2023*)
(*Neurobiology of Pain, 2023*)
(*Expert Opinion on Therapeutic Targets, 2023*)
(*Psychopharmacology, 2026, 2022, 2021*)
(*Behavioral Brain Research, 2022*)
(*Journal of Neuroimmunology, 2022*)
(*Drug and Alcohol Research, 2021*)
(*Brain Research Bulletin, 2021, 2020*)
(*Brain Research, 2020*)
(*Neurotoxicity Research, 2020*)
(*Neurotoxicology, 2020*)
(*Physiology and Behavior, 2020*)
(*Scientific Reports, 2020*)
(*Journal of Physiology and Pharmacology, 2019*)
(*PLOS One, 2019*)
(*British Journal of Pharmacology, 2018*)
(*UF Center for Addiction Research and Education Training Grant, 2021, 2020, 2019*)

SERVICE ON GRADUATE SCHOOL COMMITTEES: SERVICE ON HOSPITAL COMMITTEES:

*External Dissertation Defense Reviewer for Doctoral Candidate Kayle Dickson, PI- Christian Lehman, M.D.,
Dalhousie University, Nova Scotia, Canada
2024*

*Graduate Student Admissions and Administrative Committee
Texas Tech University Health Sciences Center School of Pharmacy
2023-2025*

*Committee on Studies member for Texas Tech University Health Sciences Center:
Anoushka Bhat (Current PhD Candidate, School of Pharmacy)
Harrison Benson (Current PhD Candidate, School of Pharmacy)
Javaria Baig (Current PhD Student, School of Medicine)*

SERVICE TO THE COMMUNITY:

SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:

Bisola Ojo

*Ph.D. Graduate Student, Department of Anesthesiology, Rutgers NJMS, Newark, NJ
(January 2024 – Current)*

Lida Khodavirdilou

*Ph.D. Graduate Student, Department of Anesthesiology, Rutgers NJMS, Newark, NJ
(June 2023 – Current)*

Kofi Frimpong-Mason

*Ph.D. Graduate Student, Department of Anesthesiology, Rutgers NJMS, Newark, NJ
(August 2022 – Current)*

Julio Zuarth Gonzalez

*Degree Conferred: Pharmaceutical Sciences Ph.D. Texas Tech University Health Sciences Center
Graduation Date: December 2024*

Maya Chopra

*Degree Conferred: Biotechnology M.S. Texas Tech University Health Sciences Center
Graduation Date: May 2024*

Yuma Ortiz

*Degree Conferred: Pharmacodynamics Ph.D. University of Florida
Graduation Date: December 2023*

SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:

Amber Asher, Ph.D.

March 2024 – May 2025

Yuma Ortiz, Ph.D.

Jan. 2024 – Nov. 2024

TEACHING RESPONSIBILITIES: (Teaching effectiveness should be addressed in nominating letter) A.

Lectures or Course Directorships

Texas Tech University Health Sciences Center School of Pharmacy, PHAR #1233 Principles of Disease, 2024- 2026 Spring Semester, Apoptosis & Necrosis, Diseases of Infancy & Childhood I - III, Neoplasia I – III, 7 hours

Texas Tech University Health Sciences Center School of Pharmacy, PHAR #3405 Integ Ther and Practice V (Neuro/Psych), 2023- 2025 Fall Semester, Bipolar Disorder Pathophysiology, Alzheimer's Disease Pathophysiology, Anesthetic Agents and Pain I, II, Opioid Pharmacology, Multiple Sclerosis Pathophysiology, Multiple Sclerosis Pharmacology, Eye Disorders Pathophysiology, 8 hours

Texas Tech University Health Sciences Center School of Pharmacy, PHAR #2401 ITTP 1: Cardio, 2023 - 2025 Fall Semester, Ischemic Heart Disease/Stroke I, II, Pharmacology of Parenteral Anticoagulants, Pharmacology of Venous Thromboembolism I, II, 5 hours

Texas Tech University Health Sciences Center Graduate School of Pharmaceutical Sciences GPSC 5435 Physiology-based Pharmacology, Fall Semester 2023 - 2025, Stroke Pathophysiology and Treatment, Anesthetic Agents and Pain, Opioid Pharmacology, 4.5 hours

*Texas Tech University Health Sciences Center Graduate School of Pharmaceutical Sciences
GPSC 5301 Topics in Drug Addiction, 2023 – 2025, 24 hours*

University of Florida College of Pharmacy, PHA 5874C Patient Care 4 Module 7: Introduction to Renal, 2020-2021 Spring Semester, 1 hour

University of Florida Graduate School of Pharmacy, SPP-I-PHA6935 Pathophysiology and Patient Assessment, Module 3 – Renal Physiology and Pathobiology, 2019-2021 Fall Semester, 8 hours

University of Florida School of Pharmacy, PHA5560 Pathophysiology and Patient Assessment, Module 3 – Renal Phys and Pathobiology, 2019-2021 Fall Semester, 8 hours

University of Florida Graduate School of Pharmacy, PHA6935 Lifecycle of a Drug, Receptor Pharmacology, Drug Targets, Animal Models, 2019-2021 Summer Semester, 3 hours

B. Research Training (other than Primary Mentorship)

*Post Doctoral Fellows: name, dates (inclusive) of training
Dr. Erin Meyer (December 2010)*

Dr. Jeffrey Rosett (October 2010 – December 2010)

Dr. Katherine Gentry (December 2009 – February 2010)

*Pre Doctoral Students: name, dates (inclusive) of training
Joshua Bilbrey (June 2019 – July 2021)*

Zachary Curry (December 2015- November 2017)

Anthony Morales (December 2015- April 2016)

Keith Allen Strand (August 2012)

Phil Brownjohn (March 2009)

GRANT SUPPORT: *(Please list in either chronological order with newest or most current first OR in reverse chronological order, as desired)*

A. Principal Investigator

- 1. Center For Plant Science and Health, Assessment of kratom use and kratom product composition in the state of Texas, 08/01/2025 - 07/31/26, \$1,028,667, Percent effort: in kind*
- 2. National Institutes of Health, Examination of sex hormone alteration on post-operative pain development and treatment, 09/01/2023 – 08/31/2028, \$1,940,000, Percent effort: 51%*
- 3. National Institutes of Health, Kratom alkaloid exposure during pregnancy, 03/01/2023 – 02/26/2025, \$118,335, Percent effort: 10%*
- 4. FL Consortium for Medical Marijuana Clinical Outcomes, Translational examination of the pharmacological interactions of medical marijuana with neuropathic pain analgesics in both male and female young and older adults, 07/01/2021 - 6/30/2022, \$68,500 Percent effort: in kind*
- 5. FL Consortium for Medical Marijuana Clinical Outcomes, Examination of the analgesic-like effects of marijuana-derived terpenes in a mouse model of neuropathic pain, 07/01/2019 - 12/31/2020, \$64,000, Percent effort: in kind*
- 6. National Institutes of Health, Inhibiting peripheral diacylglycerol lipase beta - a novel target for pain relief, 03/10/2015 – 11/14/2017, \$156,530, Percent effort: 100%*

B. Co-Investigator

1. *National Institutes of Health, Identification of novel lead EphB1/2 tyrosine kinase inhibitors targeting peripheral neuropathic pain, 03/01/2025 - 02/27/2030, \$1,937,500, Percent effort: 15%*
2. *National Institutes of Health, Research Project-2: Functionally Selective Ligands Targeting 5-HT7 Receptor as Potential Antinociceptive Agents, 09/01/2024 - 03/31/2025 \$68,000, Percent effort: in kind*
3. *National Institutes of Health, Kratom alkaloids: in vitro and in vivo pharmacological mechanisms, 04/01/2019 – 03/31/2024, \$3,626,856, Percent effort: 40%*
4. *National Institutes of Health, UF Pharmacy medications discovery and development, 12/15/2020 – 11/30/2023, \$4,754,180, Percent effort: 35%*

PUBLICATIONS: (Please list in either chronological order with newest or most current first OR in reverse chronological order, as desired; published or accepted for publication only; should be segregated into the following categories)

A. Refereed Original Article in Journal

1. **Wilkerson, J.L.;** Gentry, K.R.; Dengler, E.C.; Wallace, J.A.; Kerwin, A.A.; Alberti, L.B.; Thakur, G.A.; Makriyannis, A.; Milligan, E.D.; *Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia; Brain and Behavior, 2: 155–177, 2012*
2. **Wilkerson, J.L.;** Gentry, K.R.; Dengler, E.C.; Wallace, J.A.; Kerwin, A.A.; Kuhn, M.N.; Alberti, L.B.; Armijo, L.M.; Thakur, G.A.; Makriyannis, A.; Milligan, E.D.; *Intrathecal cannabidiol CB2R agonist, AM1710, controls pathological pain and restores basal cytokines; Pain, 153: 1091–1106, 2012*
3. Dengler, E.C.; Kerwin, A.A.; Liu, J.; Torres, S.; Olcott C.M.; Bowman, B.N.; Armijo, L.M.; Gentry, K.R.; **Wilkerson, J.;** Wallace, J.A.; Jiang, X.; Carnes, E.C.; Brinker C.J.; Milligan, E.D.; *Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord; Journal of Controlled Release, 168: 209–224, 2013*
4. Dengler, E.C.; Alberti, L.B.; Bowman, B.N.; Kerwin, A.A.; **Wilkerson, J.L.;** Moezzi D.R.; Limanovich E.; Wallace, J.A.; Milligan, E.D.; *Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain; Journal of Neuroinflammation, 92: 1–21, 2014*
5. Ignatowska-Jankowska, B.†; **Wilkerson, J.L.†;** Mustafa M.; Abdullah R.; Niphakis M.; Wiley J.L.; Cravatt, B.F.; Lichtman, A.H.; *Selective monoacylglycerol lipase inhibitors: Antinociceptive vs. cannabimimetic effects in mice; J Pharmacol Exp Ther, 353: 424–432, 2015*
6. Mukhopadhyay, P.; Baggelaar, M.; Erdelyi, K.; Cao, Z.; Cinar, R.; Fezza, F.; Ignatowska-Janowska, B.; **Wilkerson, J.;** van Gils, N.; Hansen, T.; Ruben, M.; Soethoudt, M.; Heitman, L.; Kunos, G.; Maccarrone, M.; Lichtman, A.; Pacher, P.; van der Stelt, M.; *The novel, orally available and peripherally restricted selective cannabinoid CB2-receptor partial agonist LEI-101 prevents cisplatin-induced nephrotoxicity; Br J Pharmacol, 173: 446–58, 2016*
7. **Wilkerson, J.L.;** Niphakis, M.J.; Grim, T.W.; Mustafa, M.A.; Abdullah, R.A.; Dewey, W.L.; Akbarali, H.; Banks, M.L.; Wise, L.E.; Cravatt, B.F.; Lichtman, A.H.; *Monoacylglycerol lipase inhibition produces opioid sparing effects in a mouse model of neuropathic pain; J Pharmacol Exp Ther, 357: 145–56, 2016*
8. **Wilkerson, J.L.;** Ghosh, S.; Bagdas, D.; Mason, B.L.; Crowe, M.S.; Hsu, K.L.; Wise, L.E.; Kinsey, S.G.; Damaj, M.I.; Cravatt, B.F.; Lichtman, A.H.; *Diacylglycerol lipase beta inhibition reverses nociceptive behavior in mouse models of inflammatory and neuropathic pain; Br J Pharmacol, 173: 1678–1692, 2016*
9. Bagdas, D.†; **Wilkerson, J.L.†;** Kulkarni, A.; Toma, W.; AlSharari, S.; Gul, Z.; Lichtman, A.; Papke, R.; Thakur, G.; Damaj, M.I.; *The $\alpha 7$ nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain; Br J Pharmacol, 173: 2506–2520, 2016*

10. Donvito, G.; **Wilkerson, J.L.**; Damaj, M.I.; Lichtman, A.H.; Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice; *J Pharmacol Exp Ther*, 359: 310-318, 2016
11. **Wilkerson, J.L.**; Ghosh, S.; Mustafa, M.A.; Abdullah, R.A.; Cabrera, R.; Maldonado, R.L.; Cravatt, B.F.; Lichtman, A.H.; The Endocannabinoid Hydrolysis Inhibitor SA-57 Augments the Antinociceptive Effects of Morphine and Reduces Heroin Seeking Behavior in Mice; *Neuropharm*, 114: 156-167, 2017
12. **Wilkerson, J.L.**; Donvito, G.; Grim, T.W.; Mason, B.L.; Morales, A.; Abdullah, R.A.; Ogasawara, D.; Cravatt, B.F.; Lichtman, A.H.; Investigation of Diacylglycerol Lipase Alpha Inhibition in the LPS Model of Inflammatory Pain in Mice; *J Pharmacol Exp Ther*, 363: 394-401, 2017
13. **Wilkerson, J.L.**; Curry, Z.A.; Kinlow, P.; Hsu, K.L.; van der Stelt, M.; Cravatt, B.F.; Lichtman, A.H.; Characterization of the marble burying assay as an effective measure of pain depressed behavior in mice; *Pain*, 159: 1155-65, 2018
14. Curry, Z.; **Wilkerson, J.L.**; Bagdas, D.; Kyte, S.; Patel, N.; Donvito, G.; Mustafa, M.A.; Poklis, J.; Niphakis, M.; Hsu, K.L.; Cravatt, B.F.; Gewirtz, D.A.; Damaj, M.I.; Lichtman, A.H.; Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy induced peripheral neuropathy; *J Pharmacol Exp Ther*, 366: 169-83, 2018
15. Sim-Selley, L.J.; **Wilkerson, J.L.**; Lazenka, M.F.; Welch, S.P.; Lichtman, A.H.; Selley, D.E.; Differential Tolerance to Acute and Chronic FTY720-Mediated Antinociception: Role of S1P Receptor Adaptation; *J Pharmacol Exp Ther*, 366: 509-18, 2018
16. **Wilkerson, J.L.**; Schulze, D.R.; McMahon, L.R.; Tolerance and dependence to Delta9-tetrahydrocannabinol in rhesus monkeys: Activity assessments; *PLoS One*, 14: e0209947, 2019
17. Hiranita, T.; Leon, F.; Felix, J.S.; Restrepo, L.F.; Reeves, M.E.; Pennington, A.E.; Obeng, S.; Avery, B.A.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats; *Psychopharmacology (Berl)*, 236: 2725-2734, 2019
18. **Wilkerson, J.L.**; Felix, J.S.; Restrepo, L.F.; Ansari, M.I.; Coop, A.; McMahon, L.R.; The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats; *J Pharmacol Exp Ther*, 370: 380-389, 2019
19. Navaratne, P.V.; **Wilkerson, J.L.**; Ranasinghe, K.D.; Semenova, E.; Felix, J.S.; Ghiviriga, I.; Roitberg, A.; McMahon, L.R.; Grenning, A.J.; Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery; *ChemMedChem*, 15: 728-732, 2020
20. de Moura, F.B.; **Wilkerson, J.L.**; McMahon, L.R.; Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamlamine and dihydro-beta-erythroidine in nicotine-tolerant mice; *Brain Behav*, 4: e01581, 2020
21. **Wilkerson, J.L.**; Jiang, J.; Felix, J.S.; Bray, J.K.; da Silva, L.; Gharaibeh, R.Z.; McMahon, L.R.; Schmittgen, T.D.; Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain; *Neurosci Letters*, 731: 135029, 2020
22. Corrie, L.W.; Stokes, C.; **Wilkerson, J.L.**; Carroll, F.I.; McMahon, L.R.; Papke, R.L.; Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives; *Mol Pharm*, 98: 328-342, 2020
23. **Wilkerson, J.L.**; Alberti, L.B.; Kerwin, A.A.; Ledent, C.A.; Thakur, G.A.; Makriyannis, A.; Milligan, E.D.; Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain; *Brain Behav*, 10: e01850, 2020
24. Obeng, S.; **Wilkerson, J.L.**; Leon, F.; Reeves, M.E.; Restrepo, L.F.; Gamez-Jimenez, L.R.; Patel, A.; Pennington, A.E.; Taylor, V.A.; Ho, N.P.; Braun, T.; Fortner, J.D.; Crowley, M.L.; Williamson, M.R.; Pallares, V.L.; Mottinelli, M.; Lopera-Londono, C.; McCurdy, C.R.; McMahon, L.R.; and Hiranita, T.; Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats; *J Pharmacol Exp Ther*, 376: 410-427, 2021

25. **Wilkerson, J.L.**; Felix, J.S.; Bilbrey, J.A.; McCurdy, C.R.; McMahon, L.R.; Characterization of a mouse neuropathic pain model caused by the highly active antiviral therapy (HAART) Stavudine; *Pharmacological Reports*, 73: 1457-1464, 2021
26. Bilbrey, J.A.; Felix, J. S.; McMahon, L.R.; and **Wilkerson, J.L.**; Evaluation of the terpenes β -caryophyllene, α -terpineol, and γ -terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement; *Psychopharm*, 239: 1475-1486, 2022
27. **Wilkerson, J.L.**; Alberti, L.B.; Thakur, G.A.; Makriyannis, A; and Milligan, E.D.; Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 cation channel knockout mice, while intrathecal CB2R agonists remain efficacious and reduce TRPV1 expression in the dorsal spinal cord and DRG from a rodent model of sciatic neuropathy; *Brain Res*, 1774: 147721, 2022
28. Zainul, Z.; Ma, B.; Koka, M.; **Wilkerson, J.L.**; Ortiz, Y.T.; Kerosuo, L.; Chandran, V.; Novel roles of phentolamine in protecting axon myelination, muscle atrophy, and functional recovery following nerve injury; *Scientific Reports*, 12: 3344, 2022
29. Obeng, S.; León, F.; Patel, A.; Zuarth Gonzalez, J.D.; Da Silva, L.C.; Restrepo, L.F.; Gamez-Jimenez, L.R.; Ho, N.P.; Guerrero Calvache, M.P.; Pallares, V.L.; Helmes, J.A.; Shiomitsu, S.K.; Soto, P.L.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; Hiranita, T.; Interactive Effects of μ -Opioid and Adrenergic- α 2 Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine; *J Pharmacol Exp Ther*, 383: 182-198, 2022
30. **Wilkerson, J.L.**; Hiranita, T.; Koek, W.; McMahon, L.R.; The discriminative stimulus effects of baclofen and gamma hydroxybutyrate in C57BL/6J mice; *Behav Pharmacol*, 33: 427-434, 2022
31. Kamble, S.H.; Obeng, S.; León, F.; Restrepo, L.F.; King, T.I.; Berthold, E.C.; Kanumuri, S.R.R.; Gamez-Jimenez, L.R.; Pallares, V.L.; Patel, A.; Ho, N.P.; Hampson, A.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; Sharma, A.; Hiranita, T.; Pharmacokinetic and Pharmacodynamic Consequences of CYP3A Inhibition on Mitragynine Metabolism in Rats; *J Pharmacol Exp Ther*, 385: 180-192, 2023
32. Ortiz, Y.T.; Bilbrey, J.A.; Felix, J.S.; Kienegger, E.A.; Mottinelli, M.; Mukhopadhyay, S.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; Cannabidiol and mitragynine exhibit differential interactive effects in the attenuation of paclitaxel-induced mechanical allodynia, acute antinociception, and schedule-controlled responding in mice; *Pharmacological Reports*, 75: 937-950, 2023
33. Luque-Sanchez, K.; Felix, J.S.; Bilbrey, J.A.; Restrepo, L.; Reeves, M.; McMahon, L.R.; **Wilkerson, J.L.**; Evaluation of novel epibatidine analogs in the rat nicotine drug discrimination assay and in the rat chronic constriction injury neuropathic pain model; *Adv. Drug Alcohol Res*, 3: 11622, 2023
34. S.S.; Ortiz, Y.T.; Zuarth-Gonzalez, J.; Shamir, L.; Frimpong-Manson, K.; Hossain, M.A.; Shahi, S.; Bandy, R.; Bhat, A.; Patel, D.; Diab, H.; Thompson, J.; McMahon, L.; **Wilkerson, J.L.**; German, N.; Characterization of a non-selective opioid receptor functional antagonist – implications for development as a novel opioid dependence medication; *ACS Pharmacol. Transl. Sci.*, 7: 654-666, 2024
35. Obeng, S.; Crowley, M.L.; Mottinelli, M.; León, F.; Zuarth Gonzalez, J.D.; Chen, Y.; Gamez-Jimenez, L.R.; Restrepo, L.F.; Ho, N.P.; Patel, A.; Martins Rocha, J.; Alvarez, M.A.; Thadisetti, A.M.; Park, C.R.; Pallares, V.L.C.; Milner, M.J.; Canal, C.E.; Hampson, A.J.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.** Hiranita, T.; The Mitragyna speciosa (kratom) alkaloid mitragynine: Analysis of adrenergic α 2 receptor activity in vitro and in vivo; *Eur J Pharmacol*. 980: 176863, 2024
36. Ortiz, Y.T.; Shamir, L.G.; McMahon, L.R.; **Wilkerson, J.L.** Characterization of commercially available murine fibrosarcoma NCTC-2472 cells both in vitro and as a model of bone cancer pain in vivo; *PLoS One*, 19: e0309398, 2024
37. Zuarth Gonzalez, J.D.; Mottinelli, M.; McCurdy, C.R.; de Lartigue, G.; McMahon, L.R.; **Wilkerson, J.L.**; Mitragynine and morphine produce dose-dependent bimodal action on food but not water intake in rats; *Am J Physiol Regul Integr Comp Physiol*, 327: R568-R579, 2024

38. Ortiz, Y.T.; Nguyen, T.; **Wilkerson, J.L.**; *Antinociceptive effects of intrathecal neuropeptide B/W receptor 1 agonists in mouse acute nociception, peripheral neuropathy, and inflammatory pain models*; *Pharmacol Rep.*, 2025
39. Tareq, S.; Ewida, H.A.; Zoubi, S.; Benson, H.; Patel, D.; Diab, H.; Patra, S.; Redrovan, D.; Nozohouri, E.; Bassani, T.B.; Cardoso, A.C.; Frimpong-Manson, K.; Khodavirdilou, L.; Aziz, M.T.; **Wilkerson, J.L.**; Thompson, J.; Bickel, U.; Chelikani, P.K.; Farag, A.; Ahmed, M.S.; *Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice*; *Pharmacol Res.*, 2025
40. Zuarth Gonzalez, J.D.; Ragsdale, A.K.; Mukhopadhyay, S.; McCurdy, C.R.; McMahon, L.R.; Obeng, S.; **Wilkerson, J.L.**; *Mitragynine and 7-hydroxymitragynine: Bidirectional effects on breathing in rats*. *J Pharmacol Exp Ther.*, 2025
41. **Khodavirdilou, L.**; Zuarth Gonzalez, J.D.; Mukhopadhyay, S.; Guadagnoli, N.; Obeng, S.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.** *Mitragynine reduces methamphetamine self-administration in rats without disrupting food-maintained responding*. *Psychopharmacology (Berl)*. 2026 Jul 10.

B. Books, Monographs and Chapters

1. Hiranita, T.; Obeng, S.; Sharma, A.; **Wilkerson, J.L.**; McCurdy, C.R.; McMahon, L.R.; *In vitro and in vivo pharmacology of kratom*. *Advances in Pharmacology*, Academic Press; 2022

C. Patents Held

1. *Pan EphB tyrosine kinase forward signaling inhibitors in EphB-associated diseases*, PCT/US25/42706, 08/20/2025, Harrison Benson, Prasanth Chelikani, Syed Tareq, Jenny Wilkerson, Heba Ewida, Mahmoud Salama Ahmed

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications

1. **Wilkerson, J.L.**; Milligan, E.D.; *The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief*; *ISRN Anesthesiology*, 2011: 1-19, 2011
2. Donvito, G.; Nass, S.; **Wilkerson, J.L.**; Curry, Z.A.; Schurman, L.D.; Kinsey, S.; Lichtman, A.H.; *The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain*; *Neuropsychopharm*, 43: 52-79, 2018
3. Moerke, M.J.; McMahon, L.R.; **Wilkerson, J.L.**; *More than smoke and patches: the quest for pharmacotherapies to treat tobacco use disorder*; *Pharmacological Reviews*, 72: 527-557, 2020
4. **Wilkerson, J.L.**; Deba, F.; Crowley, M.L.; Hamouda, A.K.; McMahon, L.R.; *Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators*; *Neuropharm*. 168: 108008, 2020
5. Blanton, H.L.; Barnes, R.C.; McHann, M.C.; Bilbrey, J.A.; **Wilkerson, J.L.**; Guindon, J.; *Sex differences and the endocannabinoid system in pain*; *Pharmacol Biochem Behav*, 202: 173107, 2021
6. **Wilkerson, J.L.**; Bilbrey, J.A.; Felix, J.S.; Makriyannis, A.; McMahon, L.R.; *Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?*; *Pharmacol Biochem Behav*, 206: 73192, 2021
7. Ortiz, Y.T.; McMahon, L.R.; **Wilkerson, J.L.**; *Medicinal Cannabis and Central Nervous System Disorders*. *Frontiers in Pharmacology*, 13: 881810, 2022
8. Momplaisir, N.L.; Delatte, M.; Puthenveedu, M.A.; **Wilkerson, J.**; Edwards, E.; *Thriving as members of under-represented groups in pharmacology-related careers*; *Trends Pharmacol Sci.*, 44: 849-856, 2023
9. Zuarth Gonzalez, J.; Shahbazi Nia, S.; Ortiz, Y.T.; McMahon, L.R.; German, N.; **Wilkerson, J.L.**; *Dementia, Dopamine and Medicinal Chemistry Drug Design*; *WTJOM*, 2: 1-23, 2023

10. Mukhopadhyay, S.; Gupta, S.; **Wilkerson, J.L.**; Sharma, A.; McMahon, L.R.; McCurdy, C.R.; *Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders*; *Curr Addict Rep*, 10: 304–316, 2023
11. Frimpong-Manson, K.; Ortiz, Y.T.; McMahon, L.R.; **Wilkerson, J.L.**; *Advances in Understanding Migraine Pathophysiology: A Bench to Bedside Review of Research Insights and Therapeutics*; *Frontiers in Molecular Neuroscience*, 17: 1355281, 2024
12. **Wilkerson, J.L.**; *Seeing through the Haze: Monoacylglycerol Lipase Inhibitors As Analgesics*; *J Pharmacol Exp Ther.*, 390: 288-290, 2024
13. Khodavirdilou, L.; **Wilkerson, J.L.**; *Pain in polycystic ovary syndrome: a comprehensive bedside to bench perspective on an underrecognized symptom*. *Front Pharmacol.*, 2026
14. Pareek, A.; Gupta, R.; Pareek, A.; **Wilkerson, J.**; McMahon, L.R.; Sethi, G.; Chaturgoon, A.; *Cannabinoids and skin cancer: Mechanistic insights, therapeutic potential, and translational perspectives*. *Exp Mol Pathol.*, 2026

E. Abstracts

1. Ojo, B.; Khodavirdilou, L.K.; **Wilkerson, J.L.**; *Dose Response Effect of a Selective Estrogen Receptor Modulator (SERM) on Pain Behaviors in Female Mice*, Presented at the US Association for the Study of Pain annual meeting, 2026, Abstract ID: 118
2. Khodavirdilou, L.K.; **Wilkerson, J.L.**; *Evaluating Pain Sensitivity and Behavioral Alterations in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome*, Presented at the US Association for the Study of Pain annual meeting, 2026, Abstract ID: 92
3. Frimpong-Manson, K.; **Wilkerson, J.**; *Sex and Age Affect Migraine-Like Phenotypes in a Preclinical Model of Chronic Migraine*, Presented at the US Association for the Study of Pain annual meeting, 2026, Abstract ID: 467
4. **Wilkerson, J.L.**; *The kratom alkaloid mitragynine as a novel therapeutic for cancer-related pain relief and substance use disorders*, Presented at the Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders annual meeting, 2026
5. **Wilkerson, J.L.**; *Mitragynine as a Potential Therapeutic for Methamphetamine Use Disorder*, Presented at the International Symposium on Kratom annual meeting, 2026
6. Frimpong-Manson, K.; **Wilkerson, J.**; *Age- and Sex-Dependent Inflammatory Signaling in a Preclinical Model of Chronic Migraine*, Presented at the Society for Neuroscience annual meeting, 2025
7. Khodavirdilou, L.; **Wilkerson, J.**; *Sex-Dependent Effects of Cannabis-Derived Terpenes and Interactions with Cannabidiol on Nociception and Body Temperature in Mice*, Presented at the Society for Neuroscience annual meeting, 2025
8. Khodavirdilou, L.K.; Gonzalez, J. Z.; Mukhopadhyay, S.; Guadagnoli, N.; McCurdy, C.; McMahon, L.; **Wilkerson, J.L.**; *Mitragynine as a Potential Therapeutic for Methamphetamine Use Disorder Without Impacting Food-Motivated Behavior*; Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2025, Abstract ID: 159574
9. Sakib, M.; Shahi, S.; **Wilkerson, J.L.**; German, N.; McMahon, L.R.; Obeng, S.; *Characterization of the Behavioral Effects of the Novel Atypical Dopamine Transporter Inhibitor UR-1-1-8* Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2025, Abstract ID: 170588
10. Zolali, E.; Sakib, M.; **Wilkerson, J.L.**; McMahon, L.R.; Obeng, S.; *Evaluating the Influence of CYP450 Enzyme Inducers on the Efficacy of Psilocybin as a Treatment for Neuropsychiatric Disorders*, Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2025, Abstract ID: 167358

11. Frimpong-Manson, K.; Chopra, M.; **Wilkerson, J.L.**; *Immunomodulatory Effect of α -Terpineol on Precipitated Nicotine Withdrawal Behavior in Mice*, Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2025, Abstract ID: 163724
12. Asher, A.; Montinelli, M.; Ortiz, Y.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; *Antinociceptive Effects of Speciogynine, Paynantheine, and their 9-O-Desmethyl Metabolites*, Presented at the United States Association for the Study of Pain annual meeting, 2025
13. Frimpong-Manson, K.; **Wilkerson, J.**; *Sex Differences in Inflammatory Signaling in a Preclinical Model of Chronic Migraine*, Presented at the United States Association for the Study of Pain annual meeting, 2025
14. Khodavirdilou, L.; **Wilkerson, J.**; *Sex-Dependent Effects of Cannabidiol, Beta-Caryophyllene, and Other Cannabis-Derived Terpenes on Nociception and Body Temperature in Mice*, Presented at the United States Association for the Study of Pain annual meeting, 2025
15. Ortiz, Y.T.; Mukhopadhyay, S.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; *Mitragynine Reverses Paclitaxel Chemotherapy-Induced Peripheral Neuropathy and Sarcoma Bone Pain-Induced Peripheral Neuropathy*, Presented at the International Association for the Study of Pain meeting, 2024
16. **Wilkerson, J.L.**; *The terpene α -terpineol decreases nicotine withdrawal signs in mice*, Presented at the Society for Research on Nicotine and Tobacco annual meeting, 2024
17. Zuarth Gonzalez, J.D.; Mottinelli, M.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; *The Kratom Alkaloid Mitragynine Decreases Remifentanyl Self-Administration in Rats*, Presented at the Society for Neuroscience Annual Meeting, 2022
18. Ortiz, Y.T.; Mukhopadhyay, S.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; *Mitragynine Reverses Paclitaxel Chemotherapy-Induced Peripheral Neuropathy and is Mediated via Opioid and Adrenergic Receptor Involvement*, Presented at the Society for Neuroscience annual meeting, 2022
19. Ortiz, Y.T.; Mukhopadhyay, S.; McCurdy, C.R.; McMahon, L.R.; **Wilkerson, J.L.**; *Mitragynine Reverses Paclitaxel Chemotherapy-Induced Peripheral Neuropathy and is Mediated via Opioid Receptor Involvement*, Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2022
20. **Wilkerson, J.L.**; McCurdy, C.R.; McMahon, L.R.; *Mitragynine reverses mechanical allodynia and thermal hyperalgesia in a rat model of neuropathic pain*, Presented at the International Narcotics Research Conference Meeting, 2021
21. **Wilkerson, J.L.**; *Marijuana-derived terpenes reverse mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain: possible cannabinoid receptor involvement*, Presented at the International Cannabinoid Research Society Meeting, 2021
22. **Wilkerson, J.L.**; McMahon, L.R.; *Schedule-controlled responding in mice with chemotherapy induced neuropathy*, Presented at the Behavior, Biology, and Chemistry annual meeting, 2020
23. **Wilkerson, J.L.**; *The marijuana-derived terpene beta- caryophyllene reverses mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain*, Presented at the Society for Neuroscience annual meeting, 2019
24. **Wilkerson, J.L.**; *The marijuana-derived terpene α - terpineol reverses mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain*, Presented at the International Cannabinoid Research Society annual meeting, 2019
25. **Wilkerson, J.L.**; McMahon, L.R.; *Opioid, GABAB and 5- HT1A receptor agonist combinations in a mouse model of neuropathic pain*, Presented at the College on the Problems of Drug Dependence annual meeting, 2019
26. **Wilkerson, J.L.**; Schmittgen, T.; McMahon, L.R.; *Non-coding RNAs as biomarkers for pain and opioid use*, Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2019
27. **Wilkerson, J.L.**; Schmittgen, T.; McMahon, L.R.; *Non-coding RNAs as biomarkers for pain and opioid use*, Presented at the National Institutes on Drug Abuse Genetics Symposium, 2019

28. **Wilkerson, J.L.;** McMahon, L.R.; *The effects of morphine, baclofen, and buspirone alone and in combination on schedule-controlled responding and hot plate antinociception in rats, Presented at the American Association of Pharmaceutical Scientists Meeting, 2018*
29. **Wilkerson, J.L.;** Lichtman, A.H.; *Novel methylcyclohexyl benzene derivatives: functional cannabinoid receptor mediated antinociception vs cannabimimetic effects in mice, Presented at the Society for Neuroscience annual meeting, 2015*
30. **Wilkerson, J.L.;** Lichtman, A.H.; *The marble burying assay as an effective measure of neuropathic pain depressed behavior in mice, Presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting, 2015*
31. **Wilkerson, J.L.;** Lichtman, A.H.; *Monoacylglycerol lipase inhibition produces opioid sparing effects in a mouse model of neuropathic pain, Presented at the Society for Neuroscience annual meeting, 2014*
32. **Wilkerson, J.L.;** Milligan, E.D.; *The role of the TRPV-1 receptor in the cannabinoid 2 receptor (CB2R) agonist AM1710's analgesic effects in vivo in neuropathic mice, Presented at the Society for Neuroscience annual meeting, 2012*
33. **Wilkerson, J.L.;** Milligan, E.D.; *The selective cannabinoid receptor 2 (CB2R) agonist AM1710 acts independently of cannabinoid receptor 1 (CB1R) responses in neuropathic mice, Presented at the American Pain Society annual meeting, 2012*
34. **Wilkerson, J.L.;** Milligan, E.D.; *The selective cannabinoid receptor 2 (CB2R) agonist AM1710 acts independently of cannabinoid receptor 1 (CB1R) responses in neuropathic mice, Presented at the Society for Neuroscience annual meeting, 2011*
35. **Wilkerson, J.L.;** Milligan, E.D.; *Selective cannabinoid receptor 2 (CB2) agonists administered intrathecally act as indirect agonists and differentially alter p38 MAPK production in the spinal cord and dorsal root ganglion in neuropathic rats, Presented at the Society for Neuroscience annual meeting, 2010*
36. **Wilkerson, J.L.;** Milligan, E.D.; *Administration of Cannabinoid 2 Receptor (CB2R) to the Rodent Spinal Cord Reverses Chronic Constriction Induced Allodynia, Presented at the Society for Neuroscience annual meeting, 2009*
37. **Wilkerson, J.L.;** Milligan, E.D.; *Administration of AM 1241, a Cannabinoid 2 (CB2) Receptor Selective Agonist, to the Rodent Spinal Cord Reverses Chronic Constriction Injury (CCI) Induced Allodynia, Presented at the American Pain Society annual meeting, 2009*

PRESENTATIONS: (Please list in either chronological order with newest or most current first OR in reverse chronological order, as desired)

A. Scientific (Basic Science):

1. The kratom alkaloid mitragynine as a novel therapeutic for cancer-related pain relief and substance use disorders, Behavior, Biology and Chemistry: Translational Research in Substance Use Disorders annual meeting, San Antonio, TX, 2026
2. Mitragynine as a Potential Therapeutic for Methamphetamine Use Disorder, International Symposium on Kratom annual meeting, Lake Nona, FL, 2026
3. Turning Over a New Leaf: Examining the Potential of Cannabinoids and Kratom Alkaloids as Neuropathic Pain Therapeutics, Rutgers University, Brain Health Institute and New Jersey Medical School, Department of Anesthesiology, Virtual, 2025
4. Turning Over a New Leaf: Examining the Potential of Cannabinoids and Kratom Alkaloids as Neuropathic and Cancer Pain Therapeutics, University of South Carolina, School of Pharmacy, Department of Drug Discovery and Biomedical Sciences, Columbia, SC, 2025
5. Harnessing natural products as novel therapeutics to treat pathological pain, Texas Tech University Health Sciences Center, School of Pharmacy, Department of Immunotherapeutics and Biotechnology, Abilene, TX, 2024
6. The Interactions Between Cannabidiol and Mitragynine in the Attenuation of Paclitaxel-Induced Pain, Dalhousie University, School of Medicine, Departments of Anesthesia, Pain Management & Perioperative Medicine, Pharmacology, Microbiology and Immunology, Halifax, Nova Scotia, Canada, 2024

7. Use & Misuse of Plant-Based Drugs, Symposium on Substance Use Research (SOSUR), Sponsored by Rural Drug Addiction Research Centers, Virtual, 2024
8. Preclinical Examination of Novel Pathological Pain Therapeutic Targets: A Focus on Minimizing Opioid Use, Texas Tech University Health Sciences Center, School of Medicine, Department of Pharmacology and Neuroscience, Lubbock, TX, 2023
9. The cannabis-related terpenes β -caryophyllene, α -terpineol, and γ -terpinene display differential cannabinoid receptor involvement in the mouse chronic constriction injury neuropathic pain model, Carolina Cannabinoid Collaborative Meeting, Chapel Hill, NC, 2023
10. Mitragynine: Potential Treatment for Neuropathic Pain, Kalamazoo College, Department of Chemistry and Biochemistry, Virtual, 2022
11. Mitragynine and Cannabinoid Terpenes: Potential Treatments for Neuropathic Pain, University of Mississippi, Department of BioMolecular Sciences, Virtual, 2022
12. Pharmacology and drug development response to COVID-19, Society for the Advancement of Chicanos and Native Americans in Science Annual Meeting, San Juan, PR, 2022
13. Kratom alkaloids as non-addictive analgesics, anxiolytics, and opioid dependence therapeutics: a possible mental health trifecta on and off the battlefield, Military Health Research Symposium Annual Meeting, Orlando, FL, 2022
14. Unlocking the Code of Pathological Pain in mice: Implications for Treatment Strategies that Minimize Opioid Misuse, University of Florida, College of Veterinary Medicine, Department of Physiological Sciences, Gainesville, FL, 2020
15. Mitragynine: Potential Treatment for Neuropathic Pain. Winter Conference on Brain Research Annual Meeting, Big Sky, MT, 2020
16. Unlocking the Code of Pathological Pain in mice: Implications for Treatment Strategies that Minimize Opioid Misuse, University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, FL, 2019
17. Opioid Sparing Effects of Endocannabinoid System Modulators, University of Florida, McKnight Brain Institute, Gainesville, FL, 2018
16. In Vivo Characterization of Diacylglycerol Lipase (DAGL) Beta Inhibition in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis, University of Florida, College of Pharmacy, Department of Pharmacodynamics, Gainesville, FL, 2017
18. In Vivo Characterization of Diacylglycerol Lipase (DAGL) Beta Inhibition in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis, Sanofi Genzyme, Cambridge, MA, 2017
19. Opioid Sparing Effects of Endocannabinoid System Modulators, Washington University St. Louis, Center for Clinical Pharmacology, St. Louis, MO, 2017
20. In Vivo Characterization of Diacylglycerol Lipase (DAGL) Beta Inhibition in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis, Takeda Pharmaceuticals, La Jolla, CA, 2017
21. Inhibition of diacylglycerol lipase beta (DAGL- β) is protective in the mouse experimental autoimmune encephalomyelitis model of multiple sclerosis, International Cannabinoid Research Society Meeting, Montreal, Quebec, Canada, 2017
22. Inhibition of diacylglycerol lipase alpha (DAGL- α) reverses mouse models of inflammatory and neuropathic pain, International Cannabinoid Research Society Meeting, Bukovina, Poland, 2016
23. Dual fatty acid amide hydrolase and monoacylglycerol lipase inhibition produces opioid sparing effects in a mouse model of neuropathic pain, International Cannabinoid Research Society, Wolfville, Nova Scotia, Canada, 2015
24. The marble burying assay as an effective measure of neuropathic pain depressed behavior in mice, Virginia Academy of Sciences Annual Meeting, Harrisonburg, VA, 2015
25. Monoacylglycerol lipase inhibition produces opioid sparing effects in a mouse model of neuropathic pain, Carolina Cannabinoid Collaborative Meeting, Winston-Salem, NC, 2014
26. Diacylglycerol lipase beta (DAGL- β): New evidence for inflammatory pain relief in mice, International Cannabinoid Research Society Meeting, Baveno, Italy, 2014